Gene Delivery Technologies Market (By Delivery System: Viral Gene Delivery Systems, Non-Viral Gene Delivery System, Combined Hybrid Delivery Systems; By Application: Gene therapy, Cell therapy, Vaccines, Research; By Method: Ex Vivo, In Vivo, In Vitro) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2032
The global gene delivery technologies market size accounted for USD 4.01 billion in 2022, and it is projected to surpass around USD 17.07 billion by 2032 with a compound annual growth rate (CAGR) of 15.59% during the forecast period 2023 and 2032.
Access our Healthcare Data Intelligence Tool with 10000+ Database, Visit: Towards Healthcare
The gene delivery technologies market is an industry or segment that focuses on the development, manufacturing, and commercialization of technologies or techniques used for delivering therapeutic genes. The global gene delivery technologies market offers a wide range of approaches and platforms designed to safely and effectively introduce genetic material into living organisms.
Such technologies are crucial for gene therapy. Gene therapies refer to a segment of medicinal science that deals with treating or preventing multiple diseases by silencing or modifying patients’ cells. The global market for gene delivery technologies includes numerous approaches, including various vectors, applications, and methods. At the same time, the rising understanding of molecular biology is observed to offer a bright future for the gene delivery technologies market.
The rising prevalence of chronic diseases, the accelerating pace of technological advancement, and the increasing demand for targeted therapeutics are just a few of the significant factors driving the global market for gene-delivery technologies. Advanced physical gene delivery techniques like electroporation have all seen substantial research due to advances in physics and nanotechnology. These methods are becoming more popular because of their benefits, briefness, and nontoxicity. These elements are projected to increase the demand for the products present in this market and consequently encourage operational players' organic revenue growth.
Report Coverage | Details |
Market Size in 2023 | USD 4.63 Billion |
Market Size by 2032 | USD 17.07 Billion |
Growth Rate from 2023 to 2032 | CAGR of 15.59% |
Largest Market | North America |
Base Year | 2022 |
Forecast Period | 2023 to 2032 |
Segments Covered | By Delivery System, By Application, and By Method |
Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Driver:
Improvements in the gene delivery systems
Improvements in gene delivery systems are observed to act as a significant driver for the market. Advancements in gene delivery systems enable more effective delivery of therapeutic genes to target cells or tissues. Such improvements offer expanded treatment scope by increasing the market size for gene delivery technologies.
Moreover, the improvements in the gene delivery systems assure improved safety and increased scalability; all these factors collectively boost the adoption and commercialization of gene delivery technologies.
Restraint:
High cost of treatment
Gene therapies are widely used for treating multiple inherited disorders. The high cost of such therapies limits patients to enroll themselves for the healthcare services associated with gene therapies. Usually, the high research and production cost of therapies creates challenges for patients.
The high cost of production along with the research activities affects the investments in the industry. The high cost of therapies puts a strain on healthcare budgets, especially in publicly funded healthcare systems. Governments and healthcare organizations may be hesitant to allocate substantial resources to gene delivery technologies, considering the long-term sustainability of funding such expensive treatments.
Opportunities:
Deployment of nanotechnology in gene delivery technology
Nanotechnology offers precise control over the delivery of therapeutic genes to specific cells and organs. Nanoparticles achieved by nanotechnology can be engineered to have specific surface properties that allow them to interact with target cells or organs. The deployment of nanotechnology provides stability and protection to therapeutic genes during the delivery process, which aims to improve the overall efficacy of the treatment.
In addition, the deployment of nanotechnology in gene delivery provides significant advantages in terms of combination and controlled release. With the rising efforts to bring versatility in gene delivery technologies, the penetration of nanotechnology is observed to serve multiple opportunities for market players.
The viral gene delivery system segment is expected to dominate the market during the forecast period. Lentiviruses, retroviruses, and adenoviruses are used as viral gene-delivery vectors. Viral gene delivery systems are made up of viruses that have been modified to be replication-deficient; these viruses were made sterile through reengineering and can deliver the genes to the cells for expression. Viral gene delivery employs lentiviruses, retroviruses, and adenoviruses.
Viral vectors are widely utilized as a gene delivery system; they use modified viruses to deliver therapeutic genes. The rising demand for efficient gene transfer and long-term gene expression will promote the segment's growth during the forecast period.
Non-viral vectors delivery system is another lucrative segment of the market that delivers therapeutics without utilizing viruses. The advantages, such as low immunogenicity, ease of production, and ability to deliver larger DNA payloads via non-viral delivery systems, support the growth of the segment.
The gene therapy segment acquired the largest revenue share of the market in 2022; the segment is expected to hold the largest share during the forecast period. The rapid adoption of gene therapies across the globe promotes the segment’s development. This segment includes applications such as treating genetic diseases, cancer gene therapy, and infectious diseases. The rising demand for precise therapeutic dosages for conditions such as cancer supports the development of the gene therapy application segment.
The research segment is another attractive segment in the market for application purposes; gene delivery technologies serve as an ideal tool for research laboratories. Researchers utilize gene delivery technologies for expression analysis, gene knockout studies, and functional genomics.
The ex-vivo method segment had the largest market share in 2022; the segment will continue to grow at a significant rate. The ex-vivo method segment of the gene delivery technologies market allows the delivery of genes into cells or tissues before re-implantation into the patient.
The ex-vivo methods have been extensively used in various applications, including gene therapy and even stem cell therapy. The requirement for precise genetic modification and manipulation of cells from the industry to approach an effective treatment pattern highlights the significance of the ex-vivo method segment.
North America dominated the market in 2022, the region is expected to continue to grow during the forecast period. The massive growth of gene delivery technologies market in North America is attributed to the rapid adoption of technologies in the biotechnology and healthcare sector. The prominent academic research, the presence of multiple major biotechnology companies and the region’s overall position at research and development activities supplement the market’s growth.
The market in North America is also supported by the regulatory frameworks that facilitate clinical trials. The rising emphasis on commercializing gene therapies along with the willingness of patients to spend on gene therapies promotes the growth of the market in North America.
On the other hand, Asia Pacific is expected to witness the fastest growth during the forecast period. Countries in India, China, Japan and South Korea are witnessing rapid growth in the healthcare industry. Along with this, the rising investments in advanced gene therapies are expected to promote the growth of the market in the Asia Pacific. The rising focus on research and development activities, rising prevalence of genetic disorders and the overall advancements in the biotechnology sector contribute to the growth of the market in Asia Pacific.
The government’s support also supplements the growth of the market in Asia Pacific. The South Korean government has made significant strides in gene delivery technologies, the government is also actively promoting gene therapies along with the implementation of several healthcare policies. All these elements together fuel the growth of the gene delivery technologies market in the Asia Pacific.
Segments Covered in the Report:
By Mode
By Application
By Method
By Geography
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Gene Delivery Technologies Market
5.1. COVID-19 Landscape: Gene Delivery Technologies Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Gene Delivery Technologies Market, By Delivery System
8.1. Gene Delivery Technologies Market, by Delivery System, 2023-2032
8.1.1 Viral Gene Delivery Systems
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Non-Viral Gene Delivery System
8.1.2.1. Market Revenue and Forecast (2020-2032)
8.1.3. Combined Hybrid Delivery Systems
8.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Gene Delivery Technologies Market, By Application
9.1. Gene Delivery Technologies Market, by Application, 2023-2032
9.1.1. Gene therapy
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Cell therapy
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. Vaccines
9.1.3.1. Market Revenue and Forecast (2020-2032)
9.1.4. Research
9.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Gene Delivery Technologies Market, By Method
10.1. Gene Delivery Technologies Market, by March, 2023-2032
10.1.1. Ex Vivo
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. In Vivo
10.1.2.1. Market Revenue and Forecast (2020-2032)
10.1.3. In Vitro
10.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 11. Global Gene Delivery Technologies Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Delivery System (2020-2032)
11.1.2. Market Revenue and Forecast, by Application (2020-2032)
11.1.3. Market Revenue and Forecast, by Method(2020-2032)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Delivery System (2020-2032)
11.1.4.2. Market Revenue and Forecast, by Application (2020-2032)
11.1.4.3. Market Revenue and Forecast, by Method(2020-2032)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Delivery System (2020-2032)
11.1.5.2. Market Revenue and Forecast, by Application (2020-2032)
11.1.5.3. Market Revenue and Forecast, by Method(2020-2032)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Delivery System (2020-2032)
11.2.2. Market Revenue and Forecast, by Application (2020-2032)
11.2.3. Market Revenue and Forecast, by Method(2020-2032)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Delivery System (2020-2032)
11.2.4.2. Market Revenue and Forecast, by Application (2020-2032)
11.2.4.3. Market Revenue and Forecast, by Method(2020-2032)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Delivery System (2020-2032)
11.2.5.2. Market Revenue and Forecast, by Application (2020-2032)
11.2.5.3. Market Revenue and Forecast, by Method(2020-2032)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Delivery System (2020-2032)
11.2.6.2. Market Revenue and Forecast, by Application (2020-2032)
11.2.6.3. Market Revenue and Forecast, by Method(2020-2032)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Delivery System (2020-2032)
11.2.7.2. Market Revenue and Forecast, by Application (2020-2032)
11.2.7.3. Market Revenue and Forecast, by Method(2020-2032)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Delivery System (2020-2032)
11.3.2. Market Revenue and Forecast, by Application (2020-2032)
11.3.3. Market Revenue and Forecast, by Method(2020-2032)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Delivery System (2020-2032)
11.3.4.2. Market Revenue and Forecast, by Application (2020-2032)
11.3.4.3. Market Revenue and Forecast, by Method(2020-2032)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Delivery System (2020-2032)
11.3.5.2. Market Revenue and Forecast, by Application (2020-2032)
11.3.5.3. Market Revenue and Forecast, by Method(2020-2032)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Delivery System (2020-2032)
11.3.6.2. Market Revenue and Forecast, by Application (2020-2032)
11.3.6.3. Market Revenue and Forecast, by Method(2020-2032)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Delivery System (2020-2032)
11.3.7.2. Market Revenue and Forecast, by Application (2020-2032)
11.3.7.3. Market Revenue and Forecast, by Method(2020-2032)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Delivery System (2020-2032)
11.4.2. Market Revenue and Forecast, by Application (2020-2032)
11.4.3. Market Revenue and Forecast, by Method(2020-2032)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Delivery System (2020-2032)
11.4.4.2. Market Revenue and Forecast, by Application (2020-2032)
11.4.4.3. Market Revenue and Forecast, by Method(2020-2032)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Delivery System (2020-2032)
11.4.5.2. Market Revenue and Forecast, by Application (2020-2032)
11.4.5.3. Market Revenue and Forecast, by Method(2020-2032)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Delivery System (2020-2032)
11.4.6.2. Market Revenue and Forecast, by Application (2020-2032)
11.4.6.3. Market Revenue and Forecast, by Method(2020-2032)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Delivery System (2020-2032)
11.4.7.2. Market Revenue and Forecast, by Application (2020-2032)
11.4.7.3. Market Revenue and Forecast, by Method(2020-2032)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Delivery System (2020-2032)
11.5.2. Market Revenue and Forecast, by Application (2020-2032)
11.5.3. Market Revenue and Forecast, by Method(2020-2032)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Delivery System (2020-2032)
11.5.4.2. Market Revenue and Forecast, by Application (2020-2032)
11.5.4.3. Market Revenue and Forecast, by Method(2020-2032)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Delivery System (2020-2032)
11.5.5.2. Market Revenue and Forecast, by Application (2020-2032)
11.5.5.3. Market Revenue and Forecast, by Method(2020-2032)
Chapter 12. Company Profiles
12.1. Pfizer, Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Becton, Dickinson and Company
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Novartis AG
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. F. Hoffmann-La Roche Ltd
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Thermo Fisher Scientific, Inc.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. QIAGEN
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Horizon Discovery Group Co.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. OriGene Technologies, Inc.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. SignaGen Laboratories
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Bio-Rad Laboratories, Inc.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client